Molecular insights into cancer drug resistance from a proteomics perspective

Yao An, Li Zhou, Zhao Huang, Edouard C. Nice, Haiyuan Zhang, Canhua Huang

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Introduction: Resistance to chemotherapy and development of specific and effective molecular targeted therapies are major obstacles facing current cancer treatment. Comparative proteomic approaches have been employed for the discovery of putative biomarkers associated with cancer drug resistance and have yielded a number of candidate proteins, showing great promise for both novel drug target identification and personalized medicine for the treatment of drug-resistant cancer. Areas covered: Herein, we review the recent advances and challenges in proteomics studies on cancer drug resistance with an emphasis on biomarker discovery, as well as understanding the interconnectivity of proteins in disease-related signaling pathways. In addition, we highlight the critical role that post-translational modifications (PTMs) play in the mechanisms of cancer drug resistance. Expert opinion: Revealing changes in proteome profiles and the role of PTMs in drug-resistant cancer is key to deciphering the mechanisms of treatment resistance. With the development of sensitive and specific mass spectrometry (MS)-based proteomics and related technologies, it is now possible to investigate in depth potential biomarkers and the molecular mechanisms of cancer drug resistance, assisting the development of individualized therapeutic strategies for cancer patients.

Original languageEnglish
Pages (from-to)413-429
Number of pages17
JournalExpert Review of Proteomics
Volume16
Issue number5
DOIs
Publication statusPublished - 2019

Keywords

  • biomarker discovery
  • Cancer drug resistance
  • comparative proteomics
  • CyTOF
  • mass spectrometry
  • personalized medicine
  • PTMs

Cite this

An, Yao ; Zhou, Li ; Huang, Zhao ; Nice, Edouard C. ; Zhang, Haiyuan ; Huang, Canhua. / Molecular insights into cancer drug resistance from a proteomics perspective. In: Expert Review of Proteomics. 2019 ; Vol. 16, No. 5. pp. 413-429.
@article{bd36bd5230434ac1b60bdba89c58d4d7,
title = "Molecular insights into cancer drug resistance from a proteomics perspective",
abstract = "Introduction: Resistance to chemotherapy and development of specific and effective molecular targeted therapies are major obstacles facing current cancer treatment. Comparative proteomic approaches have been employed for the discovery of putative biomarkers associated with cancer drug resistance and have yielded a number of candidate proteins, showing great promise for both novel drug target identification and personalized medicine for the treatment of drug-resistant cancer. Areas covered: Herein, we review the recent advances and challenges in proteomics studies on cancer drug resistance with an emphasis on biomarker discovery, as well as understanding the interconnectivity of proteins in disease-related signaling pathways. In addition, we highlight the critical role that post-translational modifications (PTMs) play in the mechanisms of cancer drug resistance. Expert opinion: Revealing changes in proteome profiles and the role of PTMs in drug-resistant cancer is key to deciphering the mechanisms of treatment resistance. With the development of sensitive and specific mass spectrometry (MS)-based proteomics and related technologies, it is now possible to investigate in depth potential biomarkers and the molecular mechanisms of cancer drug resistance, assisting the development of individualized therapeutic strategies for cancer patients.",
keywords = "biomarker discovery, Cancer drug resistance, comparative proteomics, CyTOF, mass spectrometry, personalized medicine, PTMs",
author = "Yao An and Li Zhou and Zhao Huang and Nice, {Edouard C.} and Haiyuan Zhang and Canhua Huang",
year = "2019",
doi = "10.1080/14789450.2019.1601561",
language = "English",
volume = "16",
pages = "413--429",
journal = "Expert Review of Proteomics",
issn = "1478-9450",
publisher = "Taylor & Francis",
number = "5",

}

Molecular insights into cancer drug resistance from a proteomics perspective. / An, Yao; Zhou, Li; Huang, Zhao; Nice, Edouard C.; Zhang, Haiyuan; Huang, Canhua.

In: Expert Review of Proteomics, Vol. 16, No. 5, 2019, p. 413-429.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Molecular insights into cancer drug resistance from a proteomics perspective

AU - An, Yao

AU - Zhou, Li

AU - Huang, Zhao

AU - Nice, Edouard C.

AU - Zhang, Haiyuan

AU - Huang, Canhua

PY - 2019

Y1 - 2019

N2 - Introduction: Resistance to chemotherapy and development of specific and effective molecular targeted therapies are major obstacles facing current cancer treatment. Comparative proteomic approaches have been employed for the discovery of putative biomarkers associated with cancer drug resistance and have yielded a number of candidate proteins, showing great promise for both novel drug target identification and personalized medicine for the treatment of drug-resistant cancer. Areas covered: Herein, we review the recent advances and challenges in proteomics studies on cancer drug resistance with an emphasis on biomarker discovery, as well as understanding the interconnectivity of proteins in disease-related signaling pathways. In addition, we highlight the critical role that post-translational modifications (PTMs) play in the mechanisms of cancer drug resistance. Expert opinion: Revealing changes in proteome profiles and the role of PTMs in drug-resistant cancer is key to deciphering the mechanisms of treatment resistance. With the development of sensitive and specific mass spectrometry (MS)-based proteomics and related technologies, it is now possible to investigate in depth potential biomarkers and the molecular mechanisms of cancer drug resistance, assisting the development of individualized therapeutic strategies for cancer patients.

AB - Introduction: Resistance to chemotherapy and development of specific and effective molecular targeted therapies are major obstacles facing current cancer treatment. Comparative proteomic approaches have been employed for the discovery of putative biomarkers associated with cancer drug resistance and have yielded a number of candidate proteins, showing great promise for both novel drug target identification and personalized medicine for the treatment of drug-resistant cancer. Areas covered: Herein, we review the recent advances and challenges in proteomics studies on cancer drug resistance with an emphasis on biomarker discovery, as well as understanding the interconnectivity of proteins in disease-related signaling pathways. In addition, we highlight the critical role that post-translational modifications (PTMs) play in the mechanisms of cancer drug resistance. Expert opinion: Revealing changes in proteome profiles and the role of PTMs in drug-resistant cancer is key to deciphering the mechanisms of treatment resistance. With the development of sensitive and specific mass spectrometry (MS)-based proteomics and related technologies, it is now possible to investigate in depth potential biomarkers and the molecular mechanisms of cancer drug resistance, assisting the development of individualized therapeutic strategies for cancer patients.

KW - biomarker discovery

KW - Cancer drug resistance

KW - comparative proteomics

KW - CyTOF

KW - mass spectrometry

KW - personalized medicine

KW - PTMs

UR - http://www.scopus.com/inward/record.url?scp=85065440692&partnerID=8YFLogxK

U2 - 10.1080/14789450.2019.1601561

DO - 10.1080/14789450.2019.1601561

M3 - Review Article

VL - 16

SP - 413

EP - 429

JO - Expert Review of Proteomics

JF - Expert Review of Proteomics

SN - 1478-9450

IS - 5

ER -